"what does the S-1 mean?"
Correction:"After 13 years GNBT could finish the Oral lyn trial"
After 13 years GNBT still could NOT finish the Oral lyn trial
1.The usual dilution,over and over again,creating downward pressure.Creditors either dump their shares right away for a quick 20% gain,or they hold their shares,but it means Generex is giving away the company for almost free,to Joe Bloodsucking Moscamto a.k.a Dietrich von Dol, the Crimson Lord of Sylvania (Vampire Count) (from the Age of War video game he plays 36 hours a day,instead of working)and his friends.So much for the $300 million or more valuation
2.After 18 years Generex is still NOT capable to find financing.Seeing everybody else is getting money left and right,i don't think they even try to find,not Steve Fellows for sure,while it is his job,he is getting paid for that all the time.
3.The sole purpose of the company to make the management,Moscamto and the Seahawk and the creditors (and Rich Steffens,Steve Frazer aka tc2000chartreader) rich...nobody is talking about saving lives,funding research,making shareholders rich
4.Until Moscamto around he will suck the blood out of the company,instead of provident a single penny for them
All wholesome fraud!
Martin Tsvetkov Dec 13, 2012
"While there is nothing wrong with raising external capital in general, doing it for the thousandth time could raise doubts, especially if the company in question has incurred a total loss of almost $360 million throughout its existence...To satisfy its financial obligations, GNBT managers have been issuing new stock like crazy for quite a while now. What is more, the company's strategy to meet its imminent cash needs is solely based on additional private placements of common stock, offerings of preferred stock, as well as convertible debt instruments.
Nevertheless, GNBT's dire financial state has not prevented its BoD from executing stock incentive plans at a breakneck speed. As of Oct. 31, the company's management had already granted approx. 30 million shares to employees, directors, consultants and advisors. As a matter of fact, GNBT's BoD have spent almost $150 million (since inception) for general and administrative purposes, including salaries and other remuneration packages. By contrast, they have invested a little less than $133 million in research and development, i.e 12% less than the total payroll."
